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As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other 
metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver 
but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hyperten-
sion, cardiovascular or cerebrovascular diseases, and chronic kidney disease. Non-alcoholic steatohepatitis, an advanced type of 
NAFLD, can aggravate these inter-organ relationships and lead to poorer outcomes. NAFLD induces insulin resistance and exac-
erbates systemic chronic inflammation and oxidative stress, which leads to organ dysfunction in extra-hepatic tissues. Although 
more research is needed to identify the pathophysiological mechanisms and causal relationship between NAFLD and cardiomet-
abolic and renal diseases, screening for heart, brain, and kidney diseases, risk assessment for diabetes, and a multidisciplinary ap-
proach for managing these patients should be highly encouraged. 
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INTRODUCTION 
As the prevalence and incidence of obesity has dramatically in-
creased worldwide, it has had a great impact on the develop-
ment of obesity-related diseases, including type 2 diabetes 
mellitus (T2DM) and cardiovascular disease (CVD), which is 
considered a global health threat to both individuals and soci-
eties. The substantial burden of obesity is not only limited to 
Western nations, but is also occurring in many Asian countries 
[1-3]. Recently, non-alcoholic fatty liver disease (NAFLD) has 
been recognized as the hepatic manifestation of metabolic syn-
drome [4] and established as a major leading cause of chronic 
liver disease [5]. Over the past two decades, the reported num-
ber of patients with NAFLD has increased, while the number 
of individuals with hepatitis B virus, hepatitis C virus, or alco-
hol-related liver disease remained stable [6]. The prevalence of 
NAFLD in Asia has been reported from 15% to 45% [3], and a 
quarter of the total Asian population is affected by this disease 
on average [7]. This high rate is similar to the global NAFLD 
prevalence [5]. 
NAFLD is characterized as the presence of more than 5% of 
lipid accumulation in the hepatocytes, excluding other liver 
disease etiologies (virus, autoimmune, alcohol, drugs, and ge-
netics) [5]. NAFLD can progress to an advanced form, non-al-
coholic steatohepatitis (NASH), which is defined by histologi-
cal findings of hepatic steatosis with hepatocyte damage/in-
flammation [5]. Both NAFLD and NASH can further develop 
into liver fibrosis, cirrhosis, and eventually hepatocellular car-
cinoma (HCC). Although the reported incidence of HCC from 
NAFLD is rare, the number of patients with NAFLD-related 
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HCC or liver transplantation are continuously increasing, 
which might suggest a significant role of NAFLD in these end-
stage hepatic complications [8,9].
NAFLD has been regarded as the hepatic phenotype of met-
abolic impairment [4], indicating one aspect of multisystem 
disease. In addition to obesity, aging and sarcopenia are also 
known to be crucial risk factors for NAFLD or NASH [10-12]. 
As aging gradually induces sarcopenia, which is linked to frail-
ty, leading to the development of cardiometabolic and renal 
diseases as well as NAFLD or NASH, NAFLD can confer sig-
nificant risks of morbidity and mortality in elderly patients in 
particular. The current review outlines the recent epidemio-
logic evidence of the extrahepatic complications of NAFLD 
and highlights the clinical relevance of NAFLD.
ASSOCIATION AND PROGRESSION TO 
CARDIOMETABOLIC AND RENAL DISEASES 
Prediabetes and type 2 diabetes mellitus in NAFLD
Traditionally, T2DM has been a well-known risk factor for 
NAFLD [12]. Although insulin resistance is common for both 
NAFLD and T2DM [13], several studies support that NAFLD 
per se can increase the risk of T2DM as well as prediabetes [14-
17]. Furthermore, the degree of hepatic steatosis is positively 
associated with future T2DM risk in a dose-dependent man-
ner [14,16]. In a large and healthy cohort study, individuals 
with NAFLD had a 2-fold higher risk for T2DM and the risk 
for T2DM was elevated up to 4-fold with an increase in hepatic 
fibrosis [16]. Even among the non-obese population, the im-
pact of NAFLD on the incidence of impaired fasting glucose 
(IFG) and T2DM was strong [17]. Moreover, this association 
remained significant regardless of insulin resistance, obesity, 
and age [14], suggesting the direct role of NAFLD in the 
pathogenesis of T2DM. Although the incident risk for T2DM 
in NAFLD was not as high as that of IFG, the presence of 
NAFLD had an additive effect on future T2DM risk among 
subjects with IFG [15]. The severity of NAFLD, NASH, signifi-
cant hepatic fibrosis, and HCC are all highly linked with diabe-
tes; thus, modalities for screening diabetes should be imple-
mented for individuals diagnosed with NAFLD [18].
Metabolic syndrome and dyslipidemia in NAFLD 
NAFLD is considered a strong predictor for metabolic syn-
drome and vice versa. Dyslipidemia can be involved in the de-
velopment of NAFLD and also occurs as a complication of 
NAFLD [19]. Currently, 20% to 80% of NAFLD patients have 
dyslipidemia, mainly characterized as high triglyceride and 
low high-density lipoprotein cholesterol (HDL-C) [19]. Al-
though the reported findings regarding low density lipoprotein 
cholesterol (LDL-C) levels are controversial, an increase or no 
difference in LDL-C levels or a higher proportion of small 
dense LDL were demonstrated across several studies [20-22]. 
Among the components of the lipid parameters, elevated non-
HDL-C is the most frequently observed in the NASH popula-
tion (low HDL-C in 63%, high triglyceride in 46%, high non-
HDL-C in 73%, and high LDL-C in 16%) [23]. An 11-year fol-
low-up study showed that NAFLD increased the incidence of 
metabolic syndrome by 50%; however, only two components 
of metabolic syndrome, waist circumference and triglyceride 
levels, had significant associations after multivariable regres-
sion analyses [24]. This evidence might support the possible 
role of NAFLD in the development of abdominal obesity and 
excessive levels of very low density lipoprotein (VLDL), which 
are essential components of insulin resistance, an underlying 
pathophysiology of metabolic syndrome. Both hepatic over-
production of VLDL and impaired lipoprotein clearance con-
tribute to dyslipidemia in NAFLD [22]. According to the pre-
vious cross-sectional study, which revealed a strong association 
among liver fat contents, LDL particle size, and apolipoprotein 
B/A-I levels, atherogenic dyslipidemia might be driven from 
liver fat itself, independent of obesity [25]. Although the sever-
ity of NASH was not associated with abnormal lipoprotein 
profiles in this cohort [25], another study demonstrated that 
NASH can promote LDL-C oxidation [19]. 
Hypertension and atherosclerosis in NAFLD
Prospective studies demonstrated that the incidence of hyper-
tension increases in NAFLD and its rate is gradually elevated 
according to the degree of NAFLD [26-28]. The odds ratio 
(OR) of incident hypertension in individuals with NAFLD 
compared to those with normal livers ranges from 1.1 to 2.1, 
according to previous studies [26,27,29]. Moreover, among 
NAFLD individuals without incident hypertension, blood 
pressure tends to increase, and high-normal systolic blood 
pressure (130 to 139 mm Hg) is more prevalent [29]. In addi-
tion, dysregulated flow-mediated vasodilatation, increased 
thickness of intima-media, and plaques in carotid arteries, 
which are well-established surrogate markers for subclinical 
atherosclerosis, are exhibited in patients with NAFLD [20]. 
The carotid artery intima-medial thickness is increased in a 
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dose-dependent manner with the degree of NAFLD or fibrosis 
stage of NASH [20,30]. In a cohort study conducted at a gener-
al health check-up, the risk for coronary artery calcification 
was 1.8-fold greater in individuals with NAFLD, and concomi-
tant NAFLD and systemic inflammation (high levels of C-re-
active protein) elevate its risk by approximately 2.4-fold [31]. 
Compared to individuals without NAFLD, the annual progres-
sion rate of coronary artery calcification was also higher in the 
NAFLD group and the positive association between NAFLD 
and coronary artery calcification progression was more evi-
dent in NAFLD regardless of subgroup analysis [32]. Although 
pathophysiologic pathways from NAFLD to atherosclerosis 
and hypertension remain elusive, a series of studies suggested 
that systemic inflammation, endothelial dysfunction, hemody-
namic alteration, and atherogenic lipid particles including 
small dense LDL are involved in NAFLD-related atheroscle-
rotic and vascular complications [31,33-35]. 
Cardiovascular disease in NAFLD
Given the strong association between NAFLD and diabetes, 
dyslipidemia, hypertension, and atherosclerosis, which are all 
established risk factors for CVD, it is not surprising that 
NAFLD subjects have a higher prevalence and incidence of 
CVD. In particular, CVD accounts for the most common 
cause of mortality in individuals with NAFLD [36], larger than 
the number of liver-related deaths [37]. The estimated 10-year 
CVD risk score is increased in individuals with NAFLD, and 
multivariable regression analyses demonstrate up to a 3.4-fold 
increase in CVD risk among advanced stages of hepatic steato-
sis [38]. In a meta-analysis analyzing 16 observational studies 
of 34,043 adults followed for 6.9 years, patients with NAFLD 
had a higher risk of fatal and non-fatal CVD events (OR, 1.64; 
95% confidence interval [CI], 1.26 to 2.13) [39]. Furthermore, 
severe NAFLD, defined either by liver histology or by a combi-
nation of radiological imaging evidence and one of three com-
ponents (high levels of serum γ-glutamyltransferase or NAFLD 
fibrosis score or high hepatic 18F-fluoro-2-deoxyglucose uptake 
on positron emission tomography), greatly increase the total 
incident CVD (OR, 2.58; 95% CI, 1.78 to 3.75) and fatal CVD 
events (OR, 3.28; 95% CI, 2.26 to 4.77) [39]. Metabolic syn-
drome, diabetes, hypertension, dyslipidemia, atherosclerosis, 
and insulin resistance can contribute to the pathophysiologic 
progression of CVD in individuals with NAFLD. Beyond these 
traditional CVD risk factors, hyperuricemia, hypoadiponec-
tinemia, and vitamin D deficiency are also involved in the as-
sociation between NAFLD and CVD [40]. Of note, NAFLD 
and NASH per se could be regarded as emerging risk factors 
for CVD. The overall consensus states that screening for CVD 
is mandatory in all people, including adolescents and children 
with NAFLD [18]. 
Cardiac structure, function, and energy metabolism in 
NAFLD 
Several limited case-control studies with a small number of 
participants provided consistent evidence that there are signifi-
cant changes in cardiac structure, function, and energy metab-
olism in individuals with NAFLD who did not have a previous 
history of heart disease. Among subjects who did not have hy-
pertension and diabetes, NAFLD was linked to early altera-
tions in echocardiographic parameters that reflect diastolic 
function and geometry in the left ventricle of the heart, while 
no significant difference was found in systolic heart function 
[41,42]. In terms of myocardial metabolic abnormalities, indi-
viduals with hepatic steatosis show a reduction in myocardial 
energy metabolism assessed by 31P-magnetic resonance spec-
troscopy both in young and non-diabetic men [43] and in pa-
tients with T2DM [44]. Among patients with T2DM, those 
with NAFLD have impairment in myocardial perfusion and 
glucose uptake, but no difference in cardiac fatty acid metabo-
lism as measured by positron emission tomography [44]. Insu-
lin-resistant condition converts preference in the energy sub-
strate utilization of the myocardium, which might induce oxi-
dative stress, and subsequent hyperinsulinemia accelerates the 
growth of cardiomyocytes. Furthermore, the dysregulation in 
the energy metabolism of the myocardium can impair left ven-
tricular contractility, resulting in an aggravation of fibrosis 
[45], which might lead to diastolic dysfunction. 
Arrhythmias in NAFLD 
Accumulating evidence strengthens the idea that NAFLD is an 
emerging risk factor for cardiac arrhythmias [46,47]. Among 
various types of arrhythmia, atrial fibrillation, QT prolonga-
tion, ventricular arrhythmias, and conduction defects are fre-
quently reported in patients with NAFLD. In a prospective 
Finnish cohort of middle-aged adults, ultrasonographically 
defined NAFLD was an independent predictor of atrial fibrilla-
tion (OR, 1.88; 95% CI, 1.03 to 3.45) [48]. A recent cross-sec-
tional study of a general population revealed that the mean QT 
interval increases according to the degree of steatosis in the liv-
er (2.55 ms vs. 6.59 ms vs. 12.13 ms for mild, moderate, and se-
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vere steatosis, respectively), and subjects with NAFLD had a 
1.87-fold increased risk for QT prolongation [46]. The preva-
lence of ventricular arrhythmia detected by 24-hour Holter 
monitoring, including non-sustained ventricular tachycardia 
and frequent premature ventricular complex (>30 times per 
hour) was higher in individuals with NAFLD among the 
T2DM population (27.3% vs. 9.8%) [47]. In this cross-section-
al study, NAFLD was associated with a 3-fold increased risk of 
ventricular arrhythmia after adjusting for history of other un-
derlying cardiac diseases and metabolic covariates [47]. 
Stroke in NAFLD 
While ischemic stroke is generally included as a composite 
endpoint of CVD that is significantly linked to NAFLD based 
on the previous section, few studies have investigated the di-
rect association between stroke and NAFLD. A case-control 
study from Canada reported a 3.3-fold higher prevalence for 
ischemic stroke in patients with elevated alanine aminotrans-
ferase, a biomarker for NAFLD [49]. Although confounding 
factors such as diabetes or obesity are not fully adjusted, pa-
tients with biochemically defined NAFLD had more severe 
forms of stroke and worse functional outcomes compared to 
those without NAFLD in a prospective cohort of acute isch-
emic stroke patients [50]. Recently, a propensity-score matched 
case-control study from Korea revealed a strong association of 
ischemic stroke risk with liver fibrosis assessed by transient 
elastography (FibroScan; EchoSens, Paris, France), with the 
OR for ischemic stroke at 1.80 (95% CI, 1.46 to 2.23) per 1 kPa 
increase in liver stiffness, but not with liver steatosis per se [51]. 
This result might indicate the importance of liver fibrosis or 
NASH on the risk of ischemic stroke. Further prospective re-
search is needed to confirm the complex link between stroke 
and the severity of NAFLD.
Albuminuria and chronic kidney disease in NAFLD 
Although chronic kidney disease (CKD) is traditionally recog-
nized as a complication of diabetes, obesity, and CVD, recent 
studies have clearly demonstrated the possibility that NAFLD 
directly affects kidney outcomes [52-55]. The prevalence of 
CKD in NAFLD patients ranged from 20% to 55%, an approxi-
mately 2-fold increase, compared to those without NAFLD 
(5% to 30%) [52]. A meta-analysis with individual participant 
data shows consistent findings that the presence and severity 
of NAFLD are associated with an increased risk and severity of 
CKD [55]. The NAFLD group had 2.1-fold and 1.8-fold in-
creased risk of prevalent and incident CKD, respectively, and 
these risks were potentiated when they had NASH (hazard ra-
tios [HRs] of 2.5 and 2.1 for prevalent and incident CKD, re-
spectively) compared to those with simple steatosis [55]. Ad-
vanced fibrosis is associated with a higher prevalence (OR, 
5.20; 95% CI, 3.14 to 8.61) and incidence (HR, 3.29; 95% CI, 
2.30 to 4.71) of CKD than non-advanced fibrosis [55]. In addi-
tion, albuminuria is more prevalent in patients with NAFLD 
[53,54], and the impairment in kidney function is significantly 
associated with the severity of NASH histology [54]; thus, the 
presence of NAFLD and the severity of fibrosis can predict the 
development of CKD regardless of other risk factors. Further 
studies are warranted to investigate whether improvement in 
NAFLD can attenuate CKD progression, and efforts are need-
ed for the early screening of renal function and albuminuria in 
NAFLD patients.
Mortality in NAFLD 
The impact of NAFLD on overall mortality apparently differs 
according to its severity. In a community-based cohort study, 
the overall survival of NAFLD patients was lower than expect-
ed in the general population (standardized mortality ratio, 
1.34; 95% CI, 1.01 to 1.76) [36]. Among NAFLD’s causes of 
death, CVD was the most common (15.5% to 25%), followed 
by extrahepatic malignancies, and then liver-related diseases 
[36,37]. In the spectrum of NAFLD, simple steatosis is not as-
sociated with increased mortality [37,56], whereas NASH or 
advanced fibrosis, as defined by either biopsy or noninvasive 
fibrosis panels, showed approximately 1.14-fold and 1.66-fold 
to 1.85-fold increased risk for overall mortality in Swedish [37] 
and United States studies, respectively [56]. In addition, this 
decline in survival seen in advanced fibrosis or NASH is al-
most certainly from cardiovascular causes [56].
POSSIBLE MECHANISM LINKING NAFLD TO 
CARDIOMETABOLIC AND RENAL DISEASES 
NAFLD shares a common denominator with cardiometabolic 
diseases and kidney diseases, such as insulin resistance, oxida-
tive stress, and systemic inflammation. It has been reported 
that visceral adipose tissue and fat accumulation in the liver al-
ter signals in lipid and glucose metabolism, resulting in in-
flammation and cellular injury in the liver and other organs 
[57]. Accelerated free fatty acid flux to the portal circulation 
induces oxidative stress and accumulated advanced glycation 
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end-products promote vascular and renal damage [58]. In ad-
dition, endothelial dysfunction, hemodynamic alteration, and 
atherogenic dyslipidemia mediate prothrombotic and profi-
brogenic factors, stimulating organ dysfunction [31,33-35]. 
Recent emerging evidence has indicated that the intestinal mi-
crobiota and its dysbiosis can both affect the progression of 
NAFLD [59] and CVD [60] through chronic inflammation in 
the immune cells and insulin resistance [52]. Moreover, inter-
organ communications between the liver and affected organs 
may exist, which should be further investigated in future re-
search (Fig. 1). 
CONCLUSIONS
NAFLD is presently regarded as an emerging risk factor and 
essential phenotype of chronic metabolic disorder beyond be-
nign liver disease. Accumulating evidence indicates that the 
presence and severity of NAFLD are strongly associated with 
the increased prevalence and incidence of other metabolic dis-
eases, including diabetes, hypertension, atherosclerosis, CVD, 
diastolic heart dysfunction, arrhythmia, and CKD, which have 
considerable impacts on global healthcare. Taken together, in-
dividuals with NAFLD should be screened for these extra-he-
patic disorders and early effective intervention on their lifestyle 
and the future development of a pharmacologic approach to 
treat NAFLD or NASH is necessary to further prevent future 
complications. 
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Fig. 1. Putative pathophysiologic mechanisms and associations between non-alcoholic fatty liver disease (NAFLD)/non-alcoholic 
steatohepatitis (NASH) and cardiometabolic and renal diseases. preDM, prediabetes mellitus; T2DM, type 2 diabetes mellitus; 
MetS, metabolic syndrome; HTN, hypertension; CKD, chronic kidney disease; CVD, cardiovascular disease. 
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